ASH 2018 | The definitive guide to multiple myeloma at ASH 2018: part II
The role of transplant in combination MM therapies: insights from ASH 2018
What is the role of transplant today in multiple myeloma (MM)? Mohamad Mohty, MD, PhD, from the University Pierre & Marie Curie, Paris, France, and Saad Usmani, MD, FACP, of the University of North Carolina School of Medicine, Chapel Hill, NC, take time to evaluate this question as they review the big news in MM from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Together they discuss the results of the GRIFFIN trial (NCT02874742) and contemplate the presentation given by Francesca Gay, MD, University of Torino, Torino, Italy, which (abstract 121) which investigated the efficacy and safety of KRd induction-ASCT-KRd consolidation (KRd-ASCT-KRd) vs. 12 cycles of KRd vs KCd induction-ASCT-KCd consolidation. These considerations bring into focus the value of measurable residual disease in clinical trials.
